MDM2 and invasive breast carcinoma: In the case of the Breast Invasive Carcinoma (BRCA) cohort from the TCGA PANCAN12 dataset, almost 8% of patients exhibit mutation(s) in TP53 and overexpression of MDM2 (59 cases).